Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.

Keywords:
Biosimilar, Infliximab, Efficacy, Immunogenicity, Adverse events
1.
European Medicines Agency: Committee for Medicinal Products for Human Use. Assessment Report, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf.
3.
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-1612.
4.
Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U: A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-1620.
7.
Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW: Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015;60:951-956.
8.
Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, Kang HW, Kim JW: Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015;30:1705-1712.
9.
Jahnsen J, Detlie TE, Vatn S, Ricanek P: Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015;9(suppl 1):45-52.
10.
Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL: Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016;10:133-140.
11.
Gecse K, Vegh Z, Kurti Z, Rutka M, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Lakner L, Patai A, Salamon A, Szamosi T, Szepes Z, Szalay B, Toth GT, Vincze A, Molnar T, Lakatos P: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort. J Crohns Colitis 2016;10(suppl 1):S43.
12.
Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T: Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 2016;pii:jjw085.
13.
Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J: Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;22:1-7.
14.
Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ: Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015;9(suppl 1):35-44.
15.
Kolar M, Duricová D, Brotlik M, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Lukas M: Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. J Crohns Colitis 2016;10(suppl 1):S45-S46.
16.
Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 2016;pii:jjw087.
17.
Bettey M, Downey L, Underhill C, Callaghan J, Rush M, Ahmed I, Cummings F: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. J Crohns Colitis 2016;10(suppl 1):S43-S44.
18.
Sieczkowska J, Jarzębicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, Oracz G, Meglicka M, Kierkus J: Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations J Crohns Colitis 2016;10:127-132.
19.
Lovasz B, Kurti Z, Rutka M, Vegh Z, Gecse K, Farkas K, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Palatka K, Patai A, Salamon A, Szamosi T, Szepes Z, Biro E, Toth GT, Vincze A, Molnar T, Lakatos P: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort. J Crohns Colitis 2016;10(suppl 1):S46.
20.
Sieczkowska J, Jarzebicka D, Oracz G, Meglicka M, Dadalski M, Kierkus J: Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease. J Crohns Colitis 2016;10(suppl 1):S413-S414.
21.
Bálint A, Farkas K, Rutka M, Végh Z, Kürti Z, Banai J, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Patai A, Salamon A, Szamosi T, Szepes Z, Tóth GT, Vincze A, Bor R, Milassin A, Nagy F, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Lakatos PL, Molnár T: Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from central European nationwide cohort. J Crohns Colitis 2016;10(suppl 1):S31.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.